The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III,
Intimation of re-appointment of Cost Auditor of the Company pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for India Business Excellence Fund III
Intimation of Analysts/Investors Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, scheduled to be held on Tuesday, September 22, 2026 at 11.00 A.M.(IST) onwards.
Intimation of Change of Corporate Identification Number (CIN) of the company.
Audio Recording of Earnings Call for the quarter ended June 30, 2026.
Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.
The Board of Directors at their meeting held on Saturday, September 05, 2026 approved the Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30, 2026
Outcome of the Board Meeting held on Saturday, September 05,2026.
Molbio Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2026 ,inter alia, to consider and approve To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026.